Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy-Reference-Cited by-同舟云学术

Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy

Published:2016-07 Issue:27 Volume:95 Page:e4157
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Huang Chung-Feng,Yeh Ming-Lun,Huang Cing-Yi,Tsai Pei-Chien,Ko Yu-Min,Chen Kuan-Yu,Lin Zu-Yau,Chen Shinn-Cherng,Dai Chia-Yen,Chuang Wan-Long,Huang Jee-Fu,Yu Ming-Lung

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference36 articles.

1. Hepatocellular carcinoma and the risk of occupational exposure;Rapisarda;World J Hepatol,2016

2. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence;Mohd Hanafiah;Hepatology,2013

3. Hepatitis C virus infection;Lauer;N Engl J Med,2001

4. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study;Davila;Gastroenterology,2004

5. Recent trends of Japanese hepatocellular carcinoma due to HCV in aging society;Hiraoka;Hepatogastroenterology,2012

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication;Clinical and Molecular Hepatology;2024-07-01

2. Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy;Clinical and Molecular Hepatology;2024-07-01

3. Metformin and Hepatocellular Carcinoma Risk Reduction in Diabetic Patients with Chronic Hepatitis C: Fact or Fiction?;Viruses;2023-12-17

4. The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area;Journal of Gastroenterology and Hepatology;2023-09-20

5. TASL, TADE, and DAROC consensus for the screening and management of hepatitis C in patients with diabetes;Journal of the Formosan Medical Association;2023-03